Liquid Biopsy Key Players, Innovation and Product Evolution

Liquid Biopsy Market Companies with Trends and Developments

• Bio-Rad Laboratories
• Biocept Inc.
• Guardant Health
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Laboratory Corporation of America Holdings
• MDxHealth SA
• QIAGEN N.V
• Thermo Fisher Scientific Inc.

Market Growth

The global liquid biopsy market size is projected to reach USD 23.94 billion by 2034, growing from USD 7.08 billion in 2025, at a CAGR of 14.5% during the forecast period from 2025 to 2034, as a result of technological advancements in cancer diagnostics, and rising preference for minimally invasive cancer diagnostics.

Liquid Biopsy Market Trends

• In January 2025, Oxford Cancer Analytics (OXcan) announced that it raised $11 million in a Series A funding round, bringing the company’s total funding raised to $16.7 million. The funding was raised to develop and commercialize novel minimally invasive liquid biopsy blood tests for the early detection of lung cancer.
• In December 2024, Renovaro, Inc.’s subsidiary Renovaro Cube entered into a strategic partnership with Nebul to advance the early detection of cancer and other diseases. The collaboration was made to harness AI technologies and high-performance computing to transform diagnostic and therapeutic modalities.
• In September 2024, SOPHiA GENETICS announced the launch of a liquid biopsy test, MSK-ACCESS, in collaboration with AstraZeneca. The collaboration was made to expand the distribution of the test to 20 locations worldwide over 12 months.

Latest Announcement by Industry Leaders

Dr. Dimitris Vavoulis, a co-ed researcher at Oxford’s Wellcome Center for Human Genetics, commented on the development of liquid biopsy tests for detecting multiple cancers that many cancers, such as pancreatic and ovarian, are difficult to detect, leading to less effective treatment. The current screening methods are limited to a few cancers and are often invasive. He said that their method is still early in development, but he envisioned that it could give patients and doctors a faster and more convenient tool to stay ahead of the disease.

Recent Developments in the Liquid Biopsy Market

• In September 2024, researchers from the Johns Hopkins Kimmel Cancer Center developed a blood test that uses AI to detect cancer-related genetic changes and protein biomarkers. AI-powered analyses may help screen women for early signs of ovarian cancer.
• In May 2024, researchers from Duarte Cancer Center in California developed a blood test, a type of liquid biopsy test, to accurately detect early-stage pancreatic cancer. The study was conducted on around 1,000 people and showed positive results for detecting both early- and late-stage pancreatic cancer.

Partner with our experts to explore the Liquid Biopsy Market at sales@towardshealthcare.com